Cis-diamminedichloroplatinum (II) in locally advanced and metastatic urothelial cancer.
Twenty-seven consecutive patients with locally extensive or metastatic urothelial cancer, primarily bladder, were given cis-diamminedichloroplatinum (II) (DDP) at a dose of 70 mg/m2 every three weeks. All patients had hydration and mannitol-induced diuresis initiated before administration of DDP. Nine patients (33%) had a partial response; 12 (45%) remained stable for an average duration of six months. Responders had a significantly greater survival than nonresponders. Although severe nephrotoxicity did not occur, patients with either a solitary or obstructed kidney were at greater risk of an increase in the serum creatinine during therapy.
D000328:Adult; D000368:Aged; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000378:metabolism; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy* / Q000378:metabolism; D002945:Cisplatin / Q000494:pharmacology / Q000627:therapeutic use*; D003404:Creatinine / Q000097:blood; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011379:Prognosis; D014571:Urologic Neoplasms / Q000188:drug therapy* / Q000378:metabolism
D003404:Creatinine; D002945:Cisplatin